share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/11/22 11:06

牛牛AI助理已提取核心訊息

Addex Therapeutics reported financial results for Q3 2024, with a net profit of CHF 8.3 million for the nine months ended September 30, 2024, primarily driven by the Neurosterix Transaction completed in April 2024. The transaction generated proceeds of CHF 5.0 million in cash and a 20% equity stake in Neurosterix valued at CHF 9.4 million.Revenue from continuing operations decreased to CHF 0.4 million for the nine months, compared to CHF 1.5 million in the same period of 2023. Operating costs from continuing operations reduced to CHF 2.7 million from CHF 3.0 million, mainly due to lower external R&D costs and D&O insurance expenses. Cash and cash equivalents stood at CHF 3.3 million as of September 30, 2024.The company retained its partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant for Parkinson's disease and post-stroke recovery. In August 2024, Indivior selected a compound for substance use disorder development, while Addex retained rights to develop a GABAB PAM program for chronic cough.
Addex Therapeutics reported financial results for Q3 2024, with a net profit of CHF 8.3 million for the nine months ended September 30, 2024, primarily driven by the Neurosterix Transaction completed in April 2024. The transaction generated proceeds of CHF 5.0 million in cash and a 20% equity stake in Neurosterix valued at CHF 9.4 million.Revenue from continuing operations decreased to CHF 0.4 million for the nine months, compared to CHF 1.5 million in the same period of 2023. Operating costs from continuing operations reduced to CHF 2.7 million from CHF 3.0 million, mainly due to lower external R&D costs and D&O insurance expenses. Cash and cash equivalents stood at CHF 3.3 million as of September 30, 2024.The company retained its partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant for Parkinson's disease and post-stroke recovery. In August 2024, Indivior selected a compound for substance use disorder development, while Addex retained rights to develop a GABAB PAM program for chronic cough.
Addex Therapeutics公佈了2024年第三季度的財務結果,截至2024年9月30日的九個月內凈利潤爲830萬瑞士法郎,主要得益於2024年4月完成的Neurosterix交易。該交易產生了500萬瑞士法郎的現金收入,以及在Neurosterix中持有20%股權,估值爲940萬瑞士法郎。持續經營的營業收入爲40萬瑞士法郎,較2023年同期的150萬瑞士法郎有所下降。持續經營的運營成本從300萬瑞士法郎減少至270萬瑞士法郎,主要由於外部研發成本和D&O保險費用的降低。截至2024年9月30日,現金及現金等價物爲330萬瑞士法郎。公司與強生和Indivior保持合作關係,擁有包括用於治療帕金森病和中風後恢復的dipraglurant在內的臨牀階段資產。2024年8月,Indivior選擇了一種用於物質使用障礙開發的Compound,而Addex保留了開發用於慢性咳嗽的GABAb PAm項目的權利。
Addex Therapeutics公佈了2024年第三季度的財務結果,截至2024年9月30日的九個月內凈利潤爲830萬瑞士法郎,主要得益於2024年4月完成的Neurosterix交易。該交易產生了500萬瑞士法郎的現金收入,以及在Neurosterix中持有20%股權,估值爲940萬瑞士法郎。持續經營的營業收入爲40萬瑞士法郎,較2023年同期的150萬瑞士法郎有所下降。持續經營的運營成本從300萬瑞士法郎減少至270萬瑞士法郎,主要由於外部研發成本和D&O保險費用的降低。截至2024年9月30日,現金及現金等價物爲330萬瑞士法郎。公司與強生和Indivior保持合作關係,擁有包括用於治療帕金森病和中風後恢復的dipraglurant在內的臨牀階段資產。2024年8月,Indivior選擇了一種用於物質使用障礙開發的Compound,而Addex保留了開發用於慢性咳嗽的GABAb PAm項目的權利。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 269

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。